Swk Hldgs Corp Stock Price, News & Analysis

SWK Holdings Corporation (Nasdaq: SWKH) announced that its CEO, Winston Black, will participate in A.G.P.'s Virtual Healthcare Symposium on November 19, 2020. The CEO will engage in one-on-one meetings with investors to discuss the company's business strategies and recent achievements. Registered investors can request a meeting time. SWK Holdings specializes in financing for the healthcare sector, partnering with product marketers to offer flexible funding solutions, while also owning Enteris Biopharma, enhancing its portfolio through innovative drug delivery technologies.

SWK Holdings Corporation (Nasdaq: SWKH) provided an update on its portfolio and partners for the 2020 calendar year, highlighting strong progress despite COVID-19 challenges. The company reported successful acquisitions, including royalties from PDL BioPharma for Coflex, Kybella, and Zalviso, totaling $4.35 million. SWK's strategy focuses on supporting small and mid-sized life sciences companies, with capital ranging from $5 million to $20 million. The subsidiary, Enteris BioPharma, is also performing well, achieving a $2.5 million milestone payment from Cara Therapeutics for Oral KORSUVA™ development.

Virtual Investor Conferences announced the availability of presentations from the Financial Services Conference for on-demand viewing on VirtualInvestorConferences.com starting September 24, 2020. Keynote features Ed Mills discussing the 2020 Election and its impact on financial services. The presentations will be accessible 24/7 for 90 days, and investors can download related materials from the virtual trade booth. This conference allows companies to engage with investors directly, presenting a modern alternative to traditional conferences.

Virtual Investor Conferences announced the agenda for the upcoming OTC Financial Services Conference on September 24, 2020. The event will begin at 9:15 AM ET with a keynote by Ed Mills from Raymond James. It will feature presentations from key industry figures, including SWK Holdings, Inc. (Nasdaq: SWKH), and provide investors the opportunity to interact directly with company executives. The conference is free for participants and will be available for on-demand replay post-event. Pre-registration is recommended for a seamless experience.

SWK Holdings Corporation (Nasdaq: SWKH) announced that its chairman and CEO, Winston Black, will present at two upcoming investor conferences. The Virtual Life Science Investor Forum is scheduled for September 17, 2020, at 12:00 PM (ET), with a live webcast available at this link. Additionally, the Financial Services Investor Conference will take place on September 24, 2020, at 10:30 AM (ET), with a livestream at this link. Investors can also access these events on the company's website.

Enteris BioPharma, a subsidiary of SWK Holdings Corporation (Nasdaq: SWKH), will host a webinar on September 29, 2020, at 1 p.m. ET, featuring Dr. John Vrettos. The webinar will focus on innovative approaches to oral peptide delivery, addressing challenges in drug formulation and delivery. Enteris' proprietary technology, Peptelligence, enables effective oral delivery of peptides and peptidomimetics, enhancing drug compliance and market opportunities. Dr. Rajiv Khosla emphasized the potential of oral peptide therapeutics to transform treatment strategies.

SWK Holdings Corporation (Nasdaq: SWKH) announced participation in the virtual 2020 Colliers Institutional Investor Conference on September 10, 2020. Chairman and CEO Winston Black will host one-on-one meetings with institutional investors to discuss the company's business strategies, recent achievements, and future milestones. SWK focuses on specialty finance solutions in the healthcare sector, partnering with product marketers to create long-term value while minimizing equity dilution. Additional information is available on their website.

SWK Holdings Corporation reported strong second quarter 2020 results, with total revenue of $7.9 million, up 40% from $5.7 million in 2019. The specialty finance segment achieved a 12.2% adjusted ROIC, with assets reaching $178.7 million, a 5.3% year-over-year increase. GAAP net income was $0.9 million or $0.07 per diluted share. The company acquired Enteris BioPharma, enhancing its portfolio. SWK was added to the Russell 3000™, 2000™, and Microcap™ Indexes, improving visibility and liquidity.